One of the 26 enrolled patients achieved complete remission and 2 of patients showed partial remission.[19] It was reported an ORR of 11.5% and the main adverse events were fatigue, anemia, and inappetence.[19] In a phase II trial (KEYNOTE-010), another anti-PD-1 antibody, Nivolumab, was used in platinum-resistant patients with ovarian cancer. Here, PDCD1 is linked to ovarian cancer.